CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Pembrolizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03661723
NCT03661723Phase 2Completed
CompareCT.gov

Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Dana-Farber Cancer Institute·interventional·Posted Sep 7, 2018·Updated Sep 19, 2024

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab, Bevacizumab, and 1 other intervention for Glioblastoma. Completed, enrolled 60 participants across 5 sites.

Detailed Summary

This research study is studying pembrolizumab and re-irradiation as possible treatments for glioblastoma. The drugs involved in this study are: * Pembrolizumab * Radiation * Bevacizumab, an FDA-approved drug for treating recurrent glioblastoma multiforme (GBM)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 7, 2018
Enrollment StartSep 28, 2018
Primary CompletionDec 9, 2021
Study CompletionAug 1, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 7.8 years ago

Interventions

Pembrolizumabdrug

Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system

Bevacizumabdrug

Bevacizumab (also known as "Avastin") is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels.

Re-irradiationradiation

Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine